Q3-osavuosiraportti
13 päivää sitten‧52 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
59 448
Myynti
Määrä
58 851
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 274 | - | - | ||
| 95 | - | - | ||
| 33 | - | - | ||
| 161 | - | - | ||
| 22 | - | - |
Ylin
1 991VWAP
Alin
1 932,5VaihtoMäärä
261,5 132 843
VWAP
Ylin
1 991Alin
1 932,5VaihtoMäärä
261,5 132 843
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 4 791 | 4 791 | 0 | 4 791 |
| Anonyymi | 128 052 | 128 052 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 4 791 | 4 791 | 0 | 4 791 |
| Anonyymi | 128 052 | 128 052 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q2-osavuosiraportti | 7.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 12.3. | |
| 2024 Q4-osavuosiraportti | 12.2. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 t sittenLikes the development in Genmab https://www.tradingview.com/x/Pg6CMbi1/
·3 t sittenImmediately, it looks like we might encounter resistance. And if we don't break it, it could drop down to 1806 ??
·1 päivä sittenIt's great that approvals are coming in for Genmap, as expected. I don't think all investors have familiarized themselves with how many things Genmap is involved in, both on its own and with others; it's absolutely wild, and yes, not everything will come to fruition, but Genmap truly has a platform that can do something, and that's also evident when other large companies show interest and have ongoing trials with Genmap. I am long in the stock myself, have been involved since the start of 2000, and am still buying more.
·10 t sittenCongratulations to Genmab and Epco in 2nd line. Expected, yet quick approval. US reacted immediately positively, or less negatively. However, the battle is not to be decided today, but in the long run. This is a step on the way.
·12.11.How can it be that the stock has risen so sharply today. What is it that I've missed. Is it the good financial report that came out a few days later or ??Poistettu·13.11.Poistettu·13.11.It's impossible to say. Analyst news, raised price targets, sector rotation, ... We so badly want to understand and know, because not knowing can feel 'dangerous' and 'uncomfortable' for most people. However, I would recommend that you learn to live with a good portion of uncertainty and ignorance - especially when it comes to individual stocks and the stock market as a whole, as well as daily and even weekly price fluctuations. If you ARE new, I would also recommend that you as soon as possible delve into the very easy-to-read "Investering uden habit" and then "The Elements of Investing" as well as "The Uncertainty Solution". There is much wisdom to be gained from these three works, and in my opinion, they are some of the best to start with. Good luck!- ·11.11.Doesn't the stock exchange close at 5 PM. There's still activity??
·11.11.Indeed, quite a few trades have been registered after 17:00, but they are all at the closing price. Happens often ....·11.11.Thanks for the answer. That makes sense. One just has to figure everything out as a newbie😊👍 
·6.11. · MuokattuThe American Genmab falls after market open. It is otherwise a good Q3 report. Are they reading plus as minus and minus as plus here under Trump?? No need to look for the foreign one. Here on Nordnet it is called Genmab ADR.·7.11.Thank you, Madagaskar and Upordown. The decline surprises me, but it's good that you have experience.·8.11.If you think what we saw yesterday was a nosedive, then the biotech sector is not for you. A drop of 60 points, or 1-2-3 % is nothing when you often see drops of 10-25-50 %. Neither Q2 nor Q3 was "very positive" as stated, but rather neutral to slightly positive, if one only looks at the financial part. Looking at the data, there has been significant headwind, which outweighs the positive financial results, in my opinion. Greetings from someone who also has some experience from the sector and especially Genmab
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
13 päivää sitten‧52 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sittenLikes the development in Genmab https://www.tradingview.com/x/Pg6CMbi1/·3 t sittenImmediately, it looks like we might encounter resistance. And if we don't break it, it could drop down to 1806 ??
- ·1 päivä sittenIt's great that approvals are coming in for Genmap, as expected. I don't think all investors have familiarized themselves with how many things Genmap is involved in, both on its own and with others; it's absolutely wild, and yes, not everything will come to fruition, but Genmap truly has a platform that can do something, and that's also evident when other large companies show interest and have ongoing trials with Genmap. I am long in the stock myself, have been involved since the start of 2000, and am still buying more.·10 t sittenCongratulations to Genmab and Epco in 2nd line. Expected, yet quick approval. US reacted immediately positively, or less negatively. However, the battle is not to be decided today, but in the long run. This is a step on the way.
- ·12.11.How can it be that the stock has risen so sharply today. What is it that I've missed. Is it the good financial report that came out a few days later or ??Poistettu·13.11.Poistettu·13.11.It's impossible to say. Analyst news, raised price targets, sector rotation, ... We so badly want to understand and know, because not knowing can feel 'dangerous' and 'uncomfortable' for most people. However, I would recommend that you learn to live with a good portion of uncertainty and ignorance - especially when it comes to individual stocks and the stock market as a whole, as well as daily and even weekly price fluctuations. If you ARE new, I would also recommend that you as soon as possible delve into the very easy-to-read "Investering uden habit" and then "The Elements of Investing" as well as "The Uncertainty Solution". There is much wisdom to be gained from these three works, and in my opinion, they are some of the best to start with. Good luck!
- ·11.11.Doesn't the stock exchange close at 5 PM. There's still activity??·11.11.Indeed, quite a few trades have been registered after 17:00, but they are all at the closing price. Happens often ....·11.11.Thanks for the answer. That makes sense. One just has to figure everything out as a newbie😊👍
- ·6.11. · MuokattuThe American Genmab falls after market open. It is otherwise a good Q3 report. Are they reading plus as minus and minus as plus here under Trump?? No need to look for the foreign one. Here on Nordnet it is called Genmab ADR.·7.11.Thank you, Madagaskar and Upordown. The decline surprises me, but it's good that you have experience.·8.11.If you think what we saw yesterday was a nosedive, then the biotech sector is not for you. A drop of 60 points, or 1-2-3 % is nothing when you often see drops of 10-25-50 %. Neither Q2 nor Q3 was "very positive" as stated, but rather neutral to slightly positive, if one only looks at the financial part. Looking at the data, there has been significant headwind, which outweighs the positive financial results, in my opinion. Greetings from someone who also has some experience from the sector and especially Genmab
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
59 448
Myynti
Määrä
58 851
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 274 | - | - | ||
| 95 | - | - | ||
| 33 | - | - | ||
| 161 | - | - | ||
| 22 | - | - |
Ylin
1 991VWAP
Alin
1 932,5VaihtoMäärä
261,5 132 843
VWAP
Ylin
1 991Alin
1 932,5VaihtoMäärä
261,5 132 843
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 4 791 | 4 791 | 0 | 4 791 |
| Anonyymi | 128 052 | 128 052 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 4 791 | 4 791 | 0 | 4 791 |
| Anonyymi | 128 052 | 128 052 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q2-osavuosiraportti | 7.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 12.3. | |
| 2024 Q4-osavuosiraportti | 12.2. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
13 päivää sitten‧52 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q2-osavuosiraportti | 7.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 12.3. | |
| 2024 Q4-osavuosiraportti | 12.2. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sittenLikes the development in Genmab https://www.tradingview.com/x/Pg6CMbi1/·3 t sittenImmediately, it looks like we might encounter resistance. And if we don't break it, it could drop down to 1806 ??
- ·1 päivä sittenIt's great that approvals are coming in for Genmap, as expected. I don't think all investors have familiarized themselves with how many things Genmap is involved in, both on its own and with others; it's absolutely wild, and yes, not everything will come to fruition, but Genmap truly has a platform that can do something, and that's also evident when other large companies show interest and have ongoing trials with Genmap. I am long in the stock myself, have been involved since the start of 2000, and am still buying more.·10 t sittenCongratulations to Genmab and Epco in 2nd line. Expected, yet quick approval. US reacted immediately positively, or less negatively. However, the battle is not to be decided today, but in the long run. This is a step on the way.
- ·12.11.How can it be that the stock has risen so sharply today. What is it that I've missed. Is it the good financial report that came out a few days later or ??Poistettu·13.11.Poistettu·13.11.It's impossible to say. Analyst news, raised price targets, sector rotation, ... We so badly want to understand and know, because not knowing can feel 'dangerous' and 'uncomfortable' for most people. However, I would recommend that you learn to live with a good portion of uncertainty and ignorance - especially when it comes to individual stocks and the stock market as a whole, as well as daily and even weekly price fluctuations. If you ARE new, I would also recommend that you as soon as possible delve into the very easy-to-read "Investering uden habit" and then "The Elements of Investing" as well as "The Uncertainty Solution". There is much wisdom to be gained from these three works, and in my opinion, they are some of the best to start with. Good luck!
- ·11.11.Doesn't the stock exchange close at 5 PM. There's still activity??·11.11.Indeed, quite a few trades have been registered after 17:00, but they are all at the closing price. Happens often ....·11.11.Thanks for the answer. That makes sense. One just has to figure everything out as a newbie😊👍
- ·6.11. · MuokattuThe American Genmab falls after market open. It is otherwise a good Q3 report. Are they reading plus as minus and minus as plus here under Trump?? No need to look for the foreign one. Here on Nordnet it is called Genmab ADR.·7.11.Thank you, Madagaskar and Upordown. The decline surprises me, but it's good that you have experience.·8.11.If you think what we saw yesterday was a nosedive, then the biotech sector is not for you. A drop of 60 points, or 1-2-3 % is nothing when you often see drops of 10-25-50 %. Neither Q2 nor Q3 was "very positive" as stated, but rather neutral to slightly positive, if one only looks at the financial part. Looking at the data, there has been significant headwind, which outweighs the positive financial results, in my opinion. Greetings from someone who also has some experience from the sector and especially Genmab
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
59 448
Myynti
Määrä
58 851
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 274 | - | - | ||
| 95 | - | - | ||
| 33 | - | - | ||
| 161 | - | - | ||
| 22 | - | - |
Ylin
1 991VWAP
Alin
1 932,5VaihtoMäärä
261,5 132 843
VWAP
Ylin
1 991Alin
1 932,5VaihtoMäärä
261,5 132 843
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 4 791 | 4 791 | 0 | 4 791 |
| Anonyymi | 128 052 | 128 052 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 4 791 | 4 791 | 0 | 4 791 |
| Anonyymi | 128 052 | 128 052 | 0 | 0 |